Notable Analyst Rating Changes 09/11: (BMY) (SYNC) (JAZZ) Upgraded; (SIRI) (TIBX) (GNOM) Downgraded

September 11, 2012 10:37 AM EDT Send to a Friend
UPGRADES
Goldman Sachs upgrades Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Conviction Buy, moving its price target from $38 to $40. Click Here for more color.

Citi raises Synacor (Nasdaq: SYNC) from Sell to Neutral.

Cowen raises Jazz Pharmaceuticals (Nasdaq: JAZZ) from Neutral to Outperform.

Goldman Sachs added Catamaran (Nasdaq: CTRX) to its Conviction Buy List with a price target of $120. Click Here for more color.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
Gabelli chops Sirius XM (Nasdaq: SIRI) from Hold to Sell. Click Here for more color.

ThinkEquity downgrades Tibco Software, Inc. (Nasdaq: TIBX) from Buy to Hold, moving its price target from $36 to $32. Click Here for more color.

Baird drops Complete Genomic (Nasdaq: GNOM) from Outperform to Neutral with a price target of $3.

Brean Murray Carret & Co. lowers Coach (NYSE: COH) from Buy to Hold.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
Jefferies initiates Clean Energy Fuels (Nasdaq: CLNE) with a Hold and $15 price target.

Credit Suisse assumes Gold Fields (NYSE: GFI) at Neutral.

Wunderlich Securities starts Intrepid Potash (NYSE: IPI) with a Buy and $26.50 target.

Credit Suisse reinstates Johnson & Johnson (NYSE: JNJ) at Neutral.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Goldman Sachs Conviction Buy List, Credit Suisse, Brean Murray Carret & Co., Citi, Jefferies & Co, Robert W Baird, ThinkEquity, Notable Analyst Rating Changes, Cowen & Co, Wunderlich Securities

Add Your Comment